Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.11 ▼ -0.11
(-2.72%)
MKT CAP: $38.2M • VOL: 9.2K
52W L $3 52W H $18
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
EXOZ // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $70.1K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.7M | -$5.9M | -$1.8M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$9.2M | -$5.9M | -$2.0M |
| EBITDA (Normalized) | -$9.6M | -$5.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$6.5M | -$8.5M | -$1.2M |
| Capital Expenditures (CapEx) | $169.9K | $396.5K | — |
| Free Cash Flow (FCF) | -$6.7M | -$8.9M | -$1.2M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.0M | $9.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.4M | $10.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EXOZ.